Purpose: Because new therapeutic approaches target tumors expressing epidermal growth factor receptor (EGFR), the aim was to undertake a thorough analysis of the expression profile of EGFR in breast cancer and to reassess its prognostic value.
Introduction
Epidermal growth factor receptor (EGFR), like c-erbB-2 are members of the type 1 family of growth factor receptors with tyrosine kinase activity [1] . In vivo, both EGFR and C-erbB-2 have been found to be overexpressed in breast cancer cells [2] . The prognostic value of c-erbB-2 has been thoroughly investigated in breast cancer and there are concording reports concluding that the overexpression of this tumor parameter is strongly associated with defavorable outcome [3] . Moreover, recent studies suggest that response to doxorubicin-based adjuvant therapy depends on C-erbB-2 status [4] . In contrast, the use of EGFR, studied widely over the last 15 years, remains controversial with regard to its prognostic value in breast cancer [5] . Moreover, studies examining the role of EGFR for predicting response to treatment are relatively rare. On the other hand, new therapeutic approaches targeting tumors expressing C-erbB-2 or EGFR have been developed [6] [7] [8] ; they are mostly based on the use of monoclonal antibodies with a particular recent clinical interest for herceptin which specifically binds to C-erbB-2 [9] . This background underlines the need for a deeper knowledge on EGFR in breast cancer and particulary, from a therapeutic point of view, the degree of EGFR overexpression in breast cancer.
The main objective of the present study was thus to more thoroughly analyse the expression profile of EGFR in breast cancer and to reappreciate its prognostic value by applying two basic complementary precepts which were not strictly followed in previous studies: to study a large cohort of patients (780 consecutive breast cancer patients) and to apply a fairly long follow-up (median follow-up of more than eight years). The most previous investigations on EGFR have used immunohistochemistry which is a method particulary well-adapted to retrospective studies on stored tumoral material but whose results may be influenced by examinator criteria and by the intrinsic quality of the antibodies. In the present study it was opted for a specific ligand binding assay which offers the possibility of a true quantification of cellular EGFR expression.
Patients and methods

Patients
From 1980 to 1993 there were 780 consecutive breast cancer patients followed in our institute and these were entered into this study. A description of the population is given in Table I . Mean age was 61 years (25-85 years). Seventy-five percent of the studied patients were menopaused. For 23 patients (3%) tumor size was not available: this was due to multifocal lesions which were not measurable. The histological grade was scored according to previously published classification [10, 11] , In 154 cases (19.8%) the tumor was not gradable. due in most cases to lobular types and to tubular types. Cytosolic estradiol receptors (ER) and progesterone receptors (PR) were assayed by ligand binding assay [12] up to 1989, and subsequently by cytosolic immunoassay with the Abbott Kit [13] , The two methods have been previously compared and give concording results [14] . Thresholds for positivity were 10 and 15 fmol/mg protein for ER and PR respectively. Among the 780 patients there were 13 cases (1.7%) where ER and PR were not given; the reason for this was the small size of the tumor sample.
All patients had undergone tumor resection with axillary lymph node dissection: 373 patients (47.8%) had mastectomy, 37 patients (5%) had subcutaneous mastectomy and 370 patients (47.2%) had tumorectomy. A locoregional treatment by radiotherapy associated with surgery was given to 60.2% of patients. Adjuvant chemotherapy was administered in 23% of patients and adjuvant hormonotherapy by tamoxifen was given to 27.4% of patients. 6.5% of patients received an hormonotherapy-chemotherapy combination as an adjuvant treatment
EGFR determination
Tumoral biopsies were obtained before any treatment was given and during surgical removal of the tumor. Tumoral samples used in the study were a part of the biopsy taken in the most representative area of the histological grade of the tumor and suitable for ER-PR determination. Average weight of samples prepared for EGFR analyses was around 350 mg. All tissue samples were stored frozen in liquid nitrogen until weekly analyses.
EGFR was assayed according to a single point method developed and validated in our laboratory [15] . In our previous paper [15] we have shown that the correlation between the single point method and classical Scatchard analysis calculated from 41 different breast carcinoma samples was very satisfactory (r = 0.973. P < 0.001). Furthermore, analysis of intra-assay and inter-assay reproducibihty revealed a comparable EGFR status in a given sample [15] , Human recombinant li5 I-labeled EGF (specific activity = 900-1400 Ci/mmol) and unlabeled recombinant human EGF were purchased from Amersham (Les Ulis, France). Frozen tumoral samples were weighed, homogenized in a buffer A containing 10 mM Tns-HCl, 1 mM EDTA. 0.5 mM DTT. and 10 mM sodium molybdate (pH 7.4). After centrifugation (800 x g for 10 min. at 4°C). the supernatant was collected and ultracentrifuged for I h (105.000 x g, 4°C). The resulting pellet, containing crude cellular membranes, was resuspended in buffer B containing 10 mM Tris-HCI. 10 mM MgCL 2 , I mM phenylmethylsulfonyl fluoride, and 0.02% NaNj (pH 7.4). An aliquot was taken for protein concentration measurement using the Bradford method. One hundred ul of '"l-labeled EGF (0.16 nM final) was incubated in duplicate with 100 ul of the membrane preparation with or without a single concentration of unlabeled EGF (50 ul; 160 nM final concentration) to allow the determination of total and non specific binding, respectively. Labeled and unlabeled EGF solutions were prepared in a buffer (10 mM Tns-HCl. 10 mM MgCI 2 . 100 ug/ml bacitracin, and 0.02% NaN 3 ) containing 0.1% BSA. The reaction was stopped by the addition of 1 ml of cold buffer B. and the tubes were immediately centrifuged at 11.000 x g (15 min at 4°C). After removal of the supernatant, y radioactivity was counted in the pellet. 
Results
There was a wide inter-patient variability in EGFR tumoral levels; these levels ranged from non-detectable to up to 789 fmol/mg protein. EGFR median value was 9 fmol/mg protein and only a small proportion of patients exhibited a relatively marked EGFR expression (Table 1) . At the time of analysis the median follow-up of the study population was 97 months with a minimum at 4 months and a maximum at 228 months. Five-year and ten-year survival rates for overall survival, disease-free survival and metastasis-free survival were 88% and 77%, 74% and 56% and 82% and 70%, respectively. Table 3 gives the results of univariate and multivariate Cox analyses which were applied to 609 patients in whom all potential prognostic factors were available. From univariate analysis it was found that histological grade, tumor size, node status and ER status were all significant predictors of survival, considering metastasis-free as well as overall survival. Using multivariate analysis only histological grade, tumor size and node status remained independant predictors of survival. The levels of tumoral EGFR were not found to be of significant predictive value. The multivariate analysis indicates that independant prognostic factors for global survival are tumor size (/> = 0.0025), node status {P = 0.001) and histological grade (P = 0.0001). Importantly, the significance of these three factors remained unchanged when adjuvant treatment (chemotherapy/hormonotherapy) was entered in the Cox analyses (unshown data).
The possible links between EGFR tumoral levels and patient outcome following adjuvant treatments were examined. There were 129 patients treated by adjuvant chemotherapy and among them EGFR tumoral levels were not linked to event-free survival or overall survival. In the same way, among the 162 patients receiving adjuvant hormonotherapy EGFR expression was not found to be a significant predictor of survival (event-free and overal).
Discussion
EGFR and C-erbB-2, representative members of the family of type 1 growth factors, have currently overpassed the stage of tumor markers to become potential tumor targets for innovative new therapies. The objective is to block the mitogenic signal driven by the overexpression of these receptors. Herceptin, a humanized murine monoclonal antibody binding to the extracel- Abbreviations. NS -not specified, NG -not gradable; ND -not done; for explanations concerning the reasons for NS. NG and ND please refer to the 'Patients and methods' section. The analyses were done in the group of 609 patients for whom all potential prognostic variables were available.
lular domain of C-erbB-2, has demonstrated a very promising activity in breast cancer [9] . EGFR extracellular domain can also be targeted by monoclonal antibodies like C225 [19] or by EGFR tyrosine kinase inhibitors like the compound ZD 1839 [20] . Early clinical trials are in progress with these EGFR tyrosine kinase inhibitors and potential benefits have been shown in a range of solid tumors [7] . In a given tumoral localisation, the application of drugs directed on EGFR protein is justified by the relative overexpression of the target. For instance, both other authors [21] and the present authors [22] have reported a marked overexpression of EGFR in a majority of head and neck tumors [21] and in glioblastomas [23] . In these latter tumoral localisations, it is clear that the application of EGFR targeted drugs would be a justified therapeutic option. We used a quantitative method by ligand binding assay allowing the determination of the expression of functional EG FRs. The distribution range of EGFR tumoral levels which was found in the present study (0-789 fmol/ mg protein) is very close to that previously reported by Fox et al. [24] , who studied a relatively large sample size (n = 370) with an identical analytical method and found levels ranging from 0 to 733 fmol/mg protein; in both studies EGFR median values were low, 20 fmol/mg protein in the study by Fox et al. [24] and 9 fmol/mg protein in the present study. From the pioneering study by Sainsbury et al. [25] , the prognostic value of EGFR has been markedly explored in breast cancer over the last two decades without a concording overall view [5, 24, 26] . Disagreement over the prognostic role of EGFR may be explained by the fact that previous studies concerned relatively small cohorts of patients with, in the majority of cases, a short follow-up. For instance, Klijn et al. compiled 40 different investigations representing 5232 patients [26] and, later, Fox et al. reported a pool of 3009 patients covering 16 independent studies [24] ; thus, in the great majority of cases, the sample size was around 150 patients per study. Most studies had inadequate follow-up time and most did not include multivariate analysis because of the limited number of patients. Thus, the aim of the present study was to provide data on EGFR in breast carcinoma by investigating a large number of patients followed on a long term period compatible with the typical slow evolution of breast cancer. Clearly, in the present study, EGFR tumoral expression was not found to be related to tumor size, tumor grade or node status. This absence of a link between EGFR and these classical breast cancer prognostic factors was also put into evidence in previous investigations based on relatively large cohorts of patients like that of Fox et al. [24] on 370 patients and that of Koenders et al. [27] on 459 patients. Likewise, the compilations of several independant studies by Klijn et al. [26] failed to demonstrate an obvious association between EGFR and these above-considered classical prognostic factors. One can thus reasonably consider that EGFR expression is, in breast cancer, totally independant of the well established prognostic factors which are tumor size, tumor grade and node status. A finding specific to the present study is the constant and significant decline in median EGFR tumoral levels according to patient age (Table 2 ). In contrast, and in agreement with previous investigations (review by Klijn et al. [26] ), the simple comparison between premenopaused patients and postmenopaused patients did not lead to significantly different EGFR distributions. There is no clear explanation for interpreting the influence of age on EGFR levels outside a possible co-regulation between ER and EGFR. It is clearly established that ER levels are increasing with age and an inverse relationship between ER status and EGFR tumor levels has been firmly put into evidence in the present study. This latter observation confirms a large majority of similar findings done by previous investigators [5, 24, 26, [28] [29] [30] . At present, there is no clear molecular explanation for helping to understand this inverse relationship between ER and EGFR in breast cancer. De Fazio et al. [31] have shown that sodium butyrate is able to induce a reciprocal modulation of the genes coding for EGFR and ER, thus suggesting that these two genes may be co-regulated. An underlying co-regulation is also suggested from the findings by Van Agthoven et al. [32] who transfected EGFR in human hormone-dependent cancer cells and noted a shift of these cells towards hormone independence.
As it is underlined in the review by Klijn et al. [26] , there is in general little agreement on the prognostic value of EGFR in breast cancer. The explanation for this may not only lie in differences in patient numbers and durations of follow-up but also in various analytical procedures with different cut-off levels. An interesting observation has been done by Klijn et al. [5] who noted that after a follow-up of five years there was a tendency for a significant association between EGFR and tumor recurrence rate {P -0.08) but this tendency was lost after 10 year follow-up (P = 0.28). Remarkably, these authors made a similar observation for ER. From a multivariate analysis, the present study, with a median follow-up at eight years, indicates that the independent prognostic factors for global survival are tumor size (P = 0.0025), node status (P -0.001) and, the most discriminant, histological grade with a P value at 0.0001. Neither ER, PR nor EGFR were found to be independent predictors of patient outcome. These conclusions remained the same when adjuvant treatment (chemotherapy/hormonotherapy) was taken into account in the Cox analyses. Koenders et al. [27] underlined the dicrepancy which exists in the literature regarding the prognostic value of EGFR for breast cancer patients receiving adjuvant therapy. In the present study, subgroup analyses tested the hypothetical link between EGFR tumoral levels and patient outcome following different adjuvant therapies (chemotherapy, hormonotherapy); in any case EGFR was found to be related to event-free survival or overall survival.
In conclusion, from the present study EGFR determination seems to be of limited value as a prognostic indicator in breast cancer. A major reason for this could lie in the fact that a mitogenic signal triggered through EGFR necessitates a specific interaction with its ligand. It has been shown in head and neck cancer for instance [21] , that analyzing both EGFR and TGF-a was of greater prognostic value than each parameter taken alone. Considering the autocrine loop by combining EGFR and TGF-a, these coupled determinations could improve the prognostic value of EGFR in breast cancer. This possibility remains to be tested in future studies.
